NIH Launches Clinical Trials of Antithrombotics for COVID-19
MONDAY, Sept. 14, 2020 -- Two of three planned adaptive phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19 have launched, according to an announcement by the National Institutes of Health (NIH).
The two current trials under the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4) Antithrombotics initiative will occur at more than 100 sites around the world and will involve patients who have not been hospitalized and those currently hospitalized. A third trial will soon start focusing on patients discharged after hospitalization for moderate-to-severe disease.
The adaptive protocol design allows different blood thinners to be started, stopped, or combined in response to emerging trial data. The ACTIV-4 Antithrombotics Inpatient trial will study the safety and effectiveness of low or high doses of heparin to prevent clotting events and improve outcomes in hospitalized COVID-19 patients. The ACTIV-4 Antithrombotics Outpatient trial will investigate whether anticoagulants or antithrombotic therapy (placebo, aspirin, or a low or therapeutic dose of apixaban) can reduce life-threatening cardiovascular or pulmonary complications in newly diagnosed COVID-19 patients not requiring hospital admission. Researchers will also collect patient data and blood samples to identify potential drug targets and biomarkers associated with the risk for developing COVID-19 complications.
"There is currently no standard of care for anticoagulation in hospitalized COVID-19 patients, and there is a desperate need for clinical evidence to guide practice," NIH Director Francis S. Collins, M.D., Ph.D., said in a statement. "Conducting trials using multiple existing networks of research sites provides the scale and speed that will get us answers faster."
© 2021 HealthDay. All rights reserved.
Posted September 2020
Further Support and Information on COVID-19
Read this next
MONDAY, Aug. 2, 2021 -- Memory problems are a common part of the postacute sequelae of COVID-19, according to a research letter published online July 29 in JAMA Network...
MONDAY, Aug. 2, 2021 -- The COVID-19 pandemic significantly disrupted breast, colorectal, and cervical cancer screenings among patients at federally qualified health centers...
MONDAY, Aug. 2, 2021 -- Breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among fully vaccinated health care workers are mainly mild or...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.